NCT01580293View on ClinicalTrials.gov

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

April 23, 2012

Primary Completion Date

June 13, 2014

Study Completion Date

November 21, 2019

Conditions

Hemophilia A

Interventions

BIOLOGICAL

BAY94-9027

Intravenous infusion of BAY94-9027

Trial Locations (59)

100

Taipei

1090

Vienna

8000

Bruges

8200

Aarhus N

10126

Turin

11217

Taipei

13005

Marseille

13210

Syracuse

17033

Hershey

20122

Milan

32207

Jacksonville

33136

Miami

35033

Rennes

35100

Izmir

35233

Daejeon

43205

Columbus

48202

Detroit

49241

Busan

50006

Changhua

51092

Reims

53127

Bonn

55455

Minneapolis

60612

Chicago

69004

Heidelberg

69677

Bron

80131

Napoli

95817

Sacramento

119228

Singapore

169608

Singapore

300011

Timișoara

5262000

Ramat Gan

85724-5024

Tucson

92103-8651

San Diego

45229-3039

Cincinnati

44106-6007

Cleveland

23298-0155

Richmond

N6A 5W9

London

050030

Medellín

080020

Baranquilla

00161

Rome

466-8560

Nagoya

663-8501

Nishinomiya

634-8522

Kashihara

160-0023

Shinjuku-ku

167-0035

Suginami

734-8551

Hiroshima

1105 AZ

Amsterdam

9713 GZ

Groningen

6229 HX

Maastricht

2545 CH

The Hague

0372

Oslo

50-367

Wroclaw

229 899

Singapore

03722

Seoul

05278

Seoul

06100

Ankara

NE1 4LP

Newcastle upon Tyne

SE1 7EH

London

S10 2JF

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY